These CD5 CAR T cells potently lysed CD5+ malignant T-cell lines and primary tumors in vitro at higher or comparable rates than previous reports, while significantly controlling tumor expansion and improving survival in T-ALL xenograft models. This evidence concerns the gene CD5 and acute lymphoblastic leukemia.